REGISTER
Sinopharm Two Deals; IgA Nephropathy New Drug FDA-Approved
Sinopharm licensed COPD drug TQC3721 to AZ ($1.9B) & expanded GSK China respiratory deals. Insilico started PhIII for AI-discovered IPF drug Rentosertib. FDA granted accelerated approval for Vera's Trutakna (Atacicept) in IgA nephropathy. Nektar began first PhIII for selective IL-2 agonist Rezpegaldesleukin in atopic dermatitis. Vertex bought Crinetics (~$10B), gaining PALSONIFY & Atumelnant.

What happened in the innovative pharma industry over the past week?

Sinopharm announced two major deals in one day with AstraZeneca and GSK; Insilico Medicine’s first AI-discovered drug Rentosertib officially launched Phase III for idiopathic pulmonary fibrosis; new IgA nephropathy drug Atacicept received FDA approval; the world’s first autoimmune IL-2 therapy initiated Phase III; Vertex acquired Crinetics for nearly $10 billion… Details below:

Sinopharm Announces Two Major Deals in One Day with AstraZeneca and GSK

On July 8, Sinopharm announced two major deals in a single day. On one side, it out-licensed global rights (excluding China) for its self-developed COPD innovative drug TQC3721 (PDE3/4 inhibitor) to global respiratory leader AstraZeneca, with a deal value up to $1.9 billion. On the other side, it further deepened its strategic collaboration with GSK, securing exclusive commercialization rights in mainland China for two globally significant respiratory products: Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) and Anoro Ellipta (umeclidinium/vilanterol).

Insilico Medicine’s First AI-Discovered Molecule Enters Phase III

On July 8, Insilico Medicine announced that its first candidate drug, Rentosertib (ISM001-055), discovered and developed entirely through its proprietary generative AI platform Pharma.AI, had officially initiated a Phase III clinical trial for idiopathic pulmonary fibrosis (IPF).

This upcoming prospective, randomized, double‑blind, placebo‑controlled, parallel‑group Phase III study will be led by Prof. Zuojun Xu from Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, as the Lead Principal Investigator, with Prof. Nanshan Zhong, Academician of the Chinese Academy of Engineering and renowned respiratory expert, and Prof. Chang Chen, President of Shanghai Pulmonary Hospital, as Co‑Leading Principal Investigators. The trial plans to evaluate the efficacy and safety of once‑daily Rentosertib over 52 weeks, with an expected enrollment of 320 subjects across 47 national centers.

New IgA Nephropathy Drug Atacicept Receives FDA Approval

On July 7, Vera Therapeutics announced that the FDA granted accelerated approval for its biologic Trutakna (Atacicept) to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of progression. Atacicept is a fully human TACI‑Fc fusion protein, representing an upstream, root‑cause‑targeting therapy for IgAN. Remegen’s Telitacicept has already been approved in China for IgAN, and the U.S. approval of Atacicept further confirms that dual‑target TACI‑Fc fusion proteins represent a viable upstream therapeutic pathway for IgAN.

World’s First Autoimmune IL‑2 Therapy Enters Phase III

On July 8, Nektar Therapeutics initiated the first registrational Phase III trial, ZENITH AD‑1, for its core pipeline candidate Rezpegaldesleukin, in patients aged 12 years and older with moderate‑to‑severe atopic dermatitis (AD). This drug is the first selective IL‑2 receptor agonist to advance to Phase III and the first IL‑2‑class therapy in the autoimmune/inflammatory space to reach this stage. Currently, the global AD market is dominated by IL‑4Rα monoclonal antibodies (e.g., dupilumab) and oral JAK inhibitors, which are inflammation‑blocking symptomatic treatments. Rezpegaldesleukin, as an immune‑homeostasis‑restoring therapy, represents a paradigm shift in autoimmune treatment—from "suppressing inflammation" toward "rebuilding immune tolerance".

Vertex Acquires Crinetics for Nearly $10 Billion

On July 6, Vertex announced the acquisition of Crinetics Pharmaceuticals for $85 per share in cash, representing a total equity value of approximately $10 billion, with a net transaction consideration of about $8.8 billion after deducting assumed cash. The acquisition is primarily driven by two core assets.

One is PALSONIFY (paltusotine) , a once‑daily oral small‑molecule drug for acromegaly that was launched in the U.S. in October 2025. Its pivotal Phase III trial data (PATHFNDR‑1 and PATHFNDR‑2) were highly impressive: among patients switching from injectable somatostatin receptor ligands (SRLs), 83% achieved the primary endpoint (IGF‑1 level ≤1× upper limit of normal), versus only 4% in the placebo group; in treatment‑naïve patients, the rate was 56% versus 5% for placebo.

The other is Atumelnant, a once‑daily oral small‑molecule ACTH receptor antagonist that directly blocks ACTH action at the adrenal cortex level, thereby controlling androgen levels at the source without reliance on high‑dose glucocorticoids. Published full data from Cohort 4 of the Phase II CAH trial showed that at Week 12, in the 80 mg morning‑dosing cohort, Atumelnant reduced morning serum androstenedione (A4) levels by a mean of 67% from baseline; 7 of 8 patients (88%) who completed 12 weeks of treatment achieved physiologic daily glucocorticoid dosing.

0
0
Loading